OpenAI unveiled GPT‑Rosalind, its first large‑language model built specifically for life‑science research. Named for DNA pioneer Rosalind Franklin, the system is designed to help scientists sort through massive data sets, generate hypotheses and speed the development of new medicines. OpenAI says the model can cut the 10‑ to 15‑year timeline typical for U.S. drug approval by improving target selection and experiment design. Available now as a research preview through a trusted‑access platform, GPT‑Rosalind also includes safeguards against misuse, as the company faces a copyright lawsuit from Ziff Davis. Read more →